Decoding incretin resistance: a mechanistic framework to reclassify therapeutic variability for GLP-1 receptor agonist therapy

This article introduces a mechanistic framework to reclassify suboptimal responses to GLP-1 receptor agonists. It defines three mechanistic subtypes of incretin resistance-receptor-level, post-receptor, and secretory-highlighting their distinct pathways and therapeutic implications. This model promotes personalized care by moving beyond the oversimplified 'non-responder' classification.